New Clinical Trial Compares Two Approaches to Spinal Fusion Bone Grafting

A new clinical trial listed on ClinicalTrials.gov is set to investigate two different approaches used to help patients achieve successful spinal fusion after ALIF (anterior lumbar interbody fusion) and XLIF (extreme lateral interbody fusion) procedures. The study will prospectively compare radiographic fusion rates and clinical outcomes between patients treated with ViviGen, a bone graft substitute, and those treated with recombinant human bone morphogenetic protein-2 (rhBMP-2), a widely used growth factor in spinal surgery.

Spinal fusion surgery is commonly performed to stabilize the spine and relieve pain in patients with degenerative disc disease or other spinal conditions. A critical factor in the success of these procedures is whether the vertebrae achieve solid bony fusion over time. Researchers hope this head-to-head comparison, focusing on single-level ALIF at L5/S1 and single-level XLIF at L4/5, will provide clearer evidence about which option offers better fusion outcomes and patient recovery experiences.

Studies like this one are valuable because they give surgeons and patients more concrete data to guide treatment decisions. By directly comparing two established options rather than relying on separate studies conducted under different conditions, the trial design allows for a more direct, apples-to-apples evaluation. This kind of comparative research is an encouraging step toward refining surgical protocols and helping ensure patients receive the most effective option for their individual needs.

If the trial proceeds as designed and produces meaningful results, it could help inform future clinical guidelines around bone grafting choices in spinal fusion surgery, potentially improving fusion success rates and patient outcomes across the field. Continued investment in this type of rigorous, prospective clinical research reflects a broader commitment to advancing evidence-based care in spine surgery.

As with all clinical trials, results will need time to mature and undergo peer review before firm conclusions can be drawn. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Comparison of Radiographic Fusion Rate and Clinical Outcome of ALIF and XLIF Performed With Either Recombinant Human Bone Morphogenetic Protein-2 or ViviGen®